{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:01:44Z","timestamp":1780495304053,"version":"3.54.1"},"reference-count":30,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>\n                    <jats:italic toggle=\"yes\">Background:<\/jats:italic>\n                    Opioid use greatly increases the risk of overdose death, as well as contracting human immunodeficiency virus (HIV) and hepatitis. Opioid agonist treatment is recommended for pregnant women who are dependent on opioids. However, there is a dearth of studies on the use of opioid agonist treatment in pregnant teenagers.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic toggle=\"yes\">Case:<\/jats:italic>\n                    Ms. A, a 15\u2009year-old G1PO in foster care, presented to our tertiary women's hospital requesting opioid agonist treatment for use of pill opioids. She reported nasal inhalation of 5\u20136 opioid tablets daily, with recent attempts to self-taper using nonprescribed buprenorphine since learning of her pregnancy. Last reported opioid use was &gt;24\u2009hours prior to admission. Urine drug testing was positive only for opioids (negative for buprenorphine and methadone). She did not exhibit significant withdrawal symptoms while hospitalized. The psychiatric treatment team recommended deferring opioid agonist treatment and pursuing outpatient substance use treatment. Unfortunately, Ms. A did not attend outpatient treatment and was lost to follow up.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic toggle=\"yes\">Discussion:<\/jats:italic>\n                    Based upon our experience and review of the studies regarding opioid use disorder (OUD) and perinatal and adolescent opioid use, we recommend that pregnant adolescents with OUD be referred to opioid agonist treatment with buprenorphine or methadone. Studies specifically addressing opioid agonist treatment in pregnant teenagers are needed.\n                  <\/jats:p>","DOI":"10.1080\/08897077.2019.1635970","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T15:50:50Z","timestamp":1564501850000},"page":"181-185","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Consideration of Opioid Agonist Treatment in A Pregnant Adolescent: A Case Report and Literature Review"],"prefix":"10.1177","volume":"41","author":[{"given":"Meredith","family":"Spada","sequence":"first","affiliation":[{"name":"UPMC Western Psychiatric Hospital, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kmiec","sequence":"additional","affiliation":[{"name":"UPMC Western Psychiatric Hospital, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody B.","family":"Glance","sequence":"additional","affiliation":[{"name":"UPMC Western Psychiatric Hospital, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Gopalan","sequence":"additional","affiliation":[{"name":"UPMC Western Psychiatric Hospital, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"key":"e_1_3_2_2_2","volume-title":"Risk and Protective Factors and Estimates of Substance Use Initiation: Results from the 2016 National Survey on Drug Use and Health.","author":"Lipari RN","year":"2017","unstructured":"Lipari RN, , Ahrnsbrak RD, , PembertonMR, , Porter JD. Risk and Protective Factors and Estimates of Substance Use Initiation: Results from the 2016 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUH-DR-FFR3-2016\/NSDUH-DR-FFR3-2016.htm."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.10.015"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.574"},{"key":"e_1_3_2_5_2","first-page":"449","article-title":"Maturation of the adolescent brain","volume":"9","author":"Arain M","year":"2013","unstructured":"Arain M, , Haque M, , Johal L, . Maturation of the adolescent brain. Neuropsychiatr Dis Treat. 2013;9:449\u2013461.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"e_1_3_2_6_2","first-page":"1","article-title":"Consensus panel chair. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction","volume":"40","author":"McNicholas L","year":"2004","unstructured":"McNicholas L. Consensus panel chair. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treat Improv Protoc. 2004;40(04-3939):1\u2013172.","journal-title":"Treat Improv Protoc."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-1210"},{"key":"e_1_3_2_8_2","author":"Center for Behavioral Health Statistics and Quality","year":"2016","unstructured":"Center for Behavioral Health Statistics and Quality. Key Substance Use and Mental Health Indicators in the United States: Results from the 2015 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2016. HHS Publication No. SMA 16-4984, NSDUH Series H-51. http:\/\/www.samhsa.gov\/data\/","journal-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2015 National Survey on Drug Use and Health"},{"key":"e_1_3_2_9_2","unstructured":"Miech RA Schulenberg JE Johnston LD Bachman JG O'Malley PM Patrick ME. National Press Release \u201cNational Adolescent Drug Trends in 2017: Findings Released.\u201d Ann Arbor Michigan: Monitoring the Future; 2017."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.04.071"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.11.005"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2011.07.033"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2016.03.002"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/19371918.2013.758975"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60358-9"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03015.x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.08.007"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.10.1157"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.13363"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000035"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5787.604"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1972.03200070079014"},{"issue":"5","key":"e_1_3_2_23_2","first-page":"853","article-title":"Adolescents and short term, low dose methadone maintenance","volume":"8","author":"Deangelis GG","year":"1973","unstructured":"Deangelis GG, , Lehmann WX. Adolescents and short term, low dose methadone maintenance. Subst Use Misuse. 1973;8(5):853\u2013863.","journal-title":"Subst Use Misuse."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/09595230500537670"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2018.2143"},{"issue":"2","key":"e_1_3_2_26_2","first-page":"e81","article-title":"Committee opinion 711: opioid use disorder in pregnancy","volume":"30","author":"ACOG","year":"2017","unstructured":"ACOG. Committee opinion 711: opioid use disorder in pregnancy. Obstet Gynecol 2017;30(2):e81\u2013e94.","journal-title":"Obstet Gynecol"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e318256496e"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005359"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000092"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0762-9"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0763-8"}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2019.1635970","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/08897077.2019.1635970","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2019.1635970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:00:49Z","timestamp":1780491649000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/08897077.2019.1635970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1080\/08897077.2019.1635970"],"URL":"https:\/\/doi.org\/10.1080\/08897077.2019.1635970","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}